See the published version of this preprint at European Journal of Medical Research.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
Jiang DeHua
XUZHOU CENTRAL HOSPITAL
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: AdipoR2belongs to seven transmembrane domains receptor family, which has been shown to have played an important role in the development of human tumor, but the underlying mechanisms are poorly understood. In this study, we found that AdipoR2 expression correlates with glioma grade. In addition, we also investigated the mechanisms behind the anti-proliferative effects of AdipoR2 in U251 cells (human glioma cell line) using the colony formation assay and WST-8 growth assay.
Methods: U251 cell line were cultured in vitro; Western Blotting was used to detect the expression of related proteins; Using Quantitative RT-PCR to detect AdipoR1and AdipoR2 expression; Detection of Cell cycle assay by flow cytometry; The gene expression profiles of glioma samples from CCGA were analyzed by Matlab and GSEA software.
Results: We found 648 upregulated genes and 436 downregulated genes correlated with AdipoR2 expression in 158 glioma samples. GSEA analysis suggested that AdipoR2 is a cell cycle–associated gene. Results of flow cytometry analysis indicated that AdipoR2 induced cell cycle G0/G1 arrest in U251 cells. Furthermore, we identified the AMPK/mTOR signaling axis to be involved in AdipoR2-induced cell cycle arrest.
Conclusions: Our results suggest that AdipoR2 may represent a novel endogenous negative regulator of GBM cell proliferation. These findings also suggested that AdipoR2may be a promising therapeutic target in GBM patients.
Keywords
AdipoR2, AMPK/mTOR, antiproliferation, glioblastoma cell
Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Figure 4
Figure 4
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at European Journal of Medical Research.
No community comments so far
Editorial decision: Minor revision
On 11 Feb, 2021
Review #2 received
Received 31 Jan, 2021
Reviewer #3 agreed
On 25 Jan, 2021
Reviewer #2 agreed
On 23 Jan, 2021
Reviewers invited
Invitations sent on 22 Jan, 2021
Reviewer #1 agreed
On 22 Jan, 2021
Review #1 received
Received 22 Jan, 2021
Editor assigned
On 19 Jan, 2021
Submission checks complete
On 19 Jan, 2021
Editor invited
On 19 Jan, 2021
Version (no preprint)
Posted 27 Dec, 2020
Editorial decision: Minor revision
On 27 Dec, 2020
Review #1 received
Received 26 Dec, 2020
Editor assigned
On 16 Dec, 2020
Reviewers invited
Invitations sent on 16 Dec, 2020
Reviewer #1 agreed
On 16 Dec, 2020
Submission checks complete
On 16 Dec, 2020
Editor invited
On 16 Dec, 2020
This version was not preprinted
Version (no preprint)
Posted 11 Dec, 2020
Editor assigned
On 11 Dec, 2020
Submission checks complete
On 11 Dec, 2020
Editor invited
On 11 Dec, 2020
This version was not preprinted
Version 1
Posted 12 Nov, 2020
No comments provided
Editorial decision: Major revision
On 24 Nov, 2020
Review #1 received
Received 23 Nov, 2020
Reviewers invited
Invitations sent on 08 Nov, 2020
Reviewer #1 agreed
On 08 Nov, 2020
Editor assigned
On 04 Nov, 2020
Submission checks complete
On 04 Nov, 2020
Editor invited
On 04 Nov, 2020
First submitted
On 03 Nov, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Medical Informatics
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at European Journal of Medical Research.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Jiang DeHua
XUZHOU CENTRAL HOSPITAL
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at European Journal of Medical Research.
No community comments so far
Editorial decision: Minor revision
On 11 Feb, 2021
Review #2 received
Received 31 Jan, 2021
Reviewer #3 agreed
On 25 Jan, 2021
Reviewer #2 agreed
On 23 Jan, 2021
Reviewers invited
Invitations sent on 22 Jan, 2021
Reviewer #1 agreed
On 22 Jan, 2021
Review #1 received
Received 22 Jan, 2021
Editor assigned
On 19 Jan, 2021
Submission checks complete
On 19 Jan, 2021
Editor invited
On 19 Jan, 2021
Version (no preprint)
Posted 27 Dec, 2020
Editorial decision: Minor revision
On 27 Dec, 2020
Review #1 received
Received 26 Dec, 2020
Editor assigned
On 16 Dec, 2020
Reviewers invited
Invitations sent on 16 Dec, 2020
Reviewer #1 agreed
On 16 Dec, 2020
Submission checks complete
On 16 Dec, 2020
Editor invited
On 16 Dec, 2020
This version was not preprinted
Version (no preprint)
Posted 11 Dec, 2020
Editor assigned
On 11 Dec, 2020
Submission checks complete
On 11 Dec, 2020
Editor invited
On 11 Dec, 2020
This version was not preprinted
Version 1
Posted 12 Nov, 2020
No comments provided
Editorial decision: Major revision
On 24 Nov, 2020
Review #1 received
Received 23 Nov, 2020
Reviewers invited
Invitations sent on 08 Nov, 2020
Reviewer #1 agreed
On 08 Nov, 2020
Editor assigned
On 04 Nov, 2020
Submission checks complete
On 04 Nov, 2020
Editor invited
On 04 Nov, 2020
First submitted
On 03 Nov, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Medical Informatics
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at European Journal of Medical Research.
Background: AdipoR2belongs to seven transmembrane domains receptor family, which has been shown to have played an important role in the development of human tumor, but the underlying mechanisms are poorly understood. In this study, we found that AdipoR2 expression correlates with glioma grade. In addition, we also investigated the mechanisms behind the anti-proliferative effects of AdipoR2 in U251 cells (human glioma cell line) using the colony formation assay and WST-8 growth assay.
Methods: U251 cell line were cultured in vitro; Western Blotting was used to detect the expression of related proteins; Using Quantitative RT-PCR to detect AdipoR1and AdipoR2 expression; Detection of Cell cycle assay by flow cytometry; The gene expression profiles of glioma samples from CCGA were analyzed by Matlab and GSEA software.
Results: We found 648 upregulated genes and 436 downregulated genes correlated with AdipoR2 expression in 158 glioma samples. GSEA analysis suggested that AdipoR2 is a cell cycle–associated gene. Results of flow cytometry analysis indicated that AdipoR2 induced cell cycle G0/G1 arrest in U251 cells. Furthermore, we identified the AMPK/mTOR signaling axis to be involved in AdipoR2-induced cell cycle arrest.
Conclusions: Our results suggest that AdipoR2 may represent a novel endogenous negative regulator of GBM cell proliferation. These findings also suggested that AdipoR2may be a promising therapeutic target in GBM patients.
Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Figure 4
Figure 4
Loading...